Education
About Us
Working with TipRanks
Follow Us
Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
ACL Stock Chart & Stats
AU$2.14
AU$0.08(2.29%)
At close: 4:00 PM EST
AU$2.14
AU$0.08(2.29%)
Day’s Range― - ―
52-Week RangeAU$2.08 - AU$3.24
Previous CloseN/A
Volume421.17K
Average Volume (3M)867.30K
Market Cap
AU$420.91M
Enterprise ValueAU$840.60M
Total Cash (Recent Filing)AU$23.14M
Total Debt (Recent Filing)AU$453.61M
Price to Earnings (P/E)23.9
Beta0.96
Next Earnings
Aug 26, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield4.6%
Share Statistics
EPS (TTM)0.07
Shares Outstanding191,320,880
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.38Price Target Upside11.21% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.17
Revenue Forecast (FY)AU$741.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent FCF growth and high cash conversion ratios indicate durable cash generation capacity. This supports dividend payments, debt servicing and reinvestment into labs and IT without relying solely on external financing, improving resilience over the next 2-6 months.
Improved Gross MarginA materially higher gross margin points to better cost control or favorable test mix (more specialized, higher-margin testing). Sustained margin improvement enhances operating leverage, giving the company scope to absorb cost inflation and incrementally increase profitability over time.
Return On EquityA high ROE reflects effective use of shareholder capital and operational efficiency. If maintained, it supports the company’s ability to generate returns for investors, attract capital for strategic projects, and fund dividends or targeted expansion in core pathology services.
Bears Say
High LeverageElevated leverage increases interest expense and refinancing risk, limiting strategic flexibility. In a capital-intensive diagnostics business, high debt can constrain investment in capacity or acquisitions and makes the company more vulnerable to demand shocks or rising rates over the medium term.
Low Net MarginA low net margin suggests a large share of revenue is consumed by operating costs, interest or other expenses, limiting retained earnings. This caps the firm’s ability to self-fund growth or rapidly deleverage, leaving profitability sensitive to cost pressures or pricing constraints.
Sluggish Revenue GrowthMinimal top-line growth indicates constrained organic demand or pricing power in core pathology services. In a volume-driven model, slow revenue expansion undermines scale benefits and makes margin improvement and debt reduction harder to achieve without structural initiatives or new contract wins.
Australian Clinical Labs Ltd News
ACL FAQ
What was Australian Clinical Labs Ltd’s price range in the past 12 months?
Australian Clinical Labs Ltd lowest share price was AU$2.08 and its highest was AU$3.24 in the past 12 months.
What is Australian Clinical Labs Ltd’s market cap?
Australian Clinical Labs Ltd’s market cap is AU$420.91M.
When is Australian Clinical Labs Ltd’s upcoming earnings report date?
Australian Clinical Labs Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 173 days.
How were Australian Clinical Labs Ltd’s earnings last quarter?
Australian Clinical Labs Ltd released its earnings results on Feb 15, 2026. The company reported AU$0.067 earnings per share for the quarter, missing the consensus estimate of AU$0.073 by -AU$0.006.
Is Australian Clinical Labs Ltd overvalued?
According to Wall Street analysts Australian Clinical Labs Ltd’s price is currently Undervalued.
Does Australian Clinical Labs Ltd pay dividends?
Australian Clinical Labs Ltd pays a Semiannually dividend of AU$0.09 which represents an annual dividend yield of 4.6%. See more information on Australian Clinical Labs Ltd dividends here
What is Australian Clinical Labs Ltd’s EPS estimate?
Australian Clinical Labs Ltd’s EPS estimate is 0.1.
How many shares outstanding does Australian Clinical Labs Ltd have?
Australian Clinical Labs Ltd has 191,320,880 shares outstanding.
What happened to Australian Clinical Labs Ltd’s price movement after its last earnings report?
Australian Clinical Labs Ltd reported an EPS of AU$0.067 in its last earnings report, missing expectations of AU$0.073. Following the earnings report the stock price went up 6.612%.
Which hedge fund is a major shareholder of Australian Clinical Labs Ltd?
Currently, no hedge funds are holding shares in AU:ACL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Australian Clinical Labs Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$2.38 (11.21% Upside)
AU$2.38 (11.21% Upside)
Insider Transactions
Bought Shares
Worth AU$50.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
18.59%
Trailing 12-Months
Asset Growth
-3.07%
Trailing 12-Months
Company Description
Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
ACL Stock 12 Month Forecast
Average Price Target
AU$2.38
▲(11.21% Upside)
Technical Analysis
Options Prices
Currently, No data available
---